Promoting The Recruitment, Engagement, And Reinvigoration of Effector T Cells via An Injectable Hydrogel with A Supramolecular Binding Capability for Cancer Immunotherapy

Yueqiang Zhu,Liangjie Jin,Junbin Chen,Miao Su,Tianmeng Sun,Xianzhu Yang

DOI: https://doi.org/10.1002/adma.202309667

IF: 29.4

2023-10-10

Advanced Materials

Abstract:T cells play a basic and key role in immunotherapy against solid tumors, and efficiently recruiting them into neoplastic foci and sustaining long‐term effector function are consistent goals that remain a critical challenge. Here, an injectable alginate‐based hydrogel with abundant β‐cyclodextrin (ALG‐βCD) sites was developed and intratumorally injected to recruit CCR9+CD8+ T cells (a subset of T cells with robust antitumor activity) via the trapped chemokine CCL25. In the meantime, an intravenously injected adamantane‐decorated anti‐PD1 antibody (Ad‐aPD1) would hitchhike on recruited CCR9+CD8+ T cells to achieve the improved intratumoral accumulation of Ad‐aPD1. Moreover, the Ad‐PD1 and Ad‐PDL1 antibodies were immobilized in the ALG‐βCD hydrogel through supramolecular host‐guest interactions of Ad and βCD, which facilitated engagement between CD8+ T cells and tumor cells and reinvigorated CD8+ T cells to avoid exhaustion. Base on this treatment strategy, T cell‐mediated anticancer activity was promoted at multiple levels, eventually achieving superior antitumor efficacy in both orthotopic and postsurgical B16‐F10 tumor models. This article is protected by copyright. All rights reserved

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology

What problem does this paper attempt to address?

The paper attempts to address the issue of how to effectively recruit, activate, and maintain the long-term function of effector T cells (particularly CCR9+CD8+ T cells with strong anti-tumor activity) in tumor tissues to enhance the efficacy of cancer immunotherapy. Specifically, the paper proposes an injectable hydrogel system (RER-T system) to achieve this goal through the following methods:

1. **Recruitment**: Utilizing the chemokine CCL25 captured in the hydrogel to attract CCR9+CD8+ T cells into the tumor tissue.
2. **Binding and Activation**: Fixing anti-PD1 and anti-PDL1 antibodies in the hydrogel through supramolecular interactions to promote the binding of CD8+ T cells to tumor cells and reactivating these T cells to prevent their exhaustion.
3. **Enhanced Accumulation**: Intravenous injection of modified anti-PD1 antibodies (Ad-aPD1) allows them to "hitch a ride" by attaching to the recruited CCR9+CD8+ T cells, thereby increasing their accumulation in the tumor tissue.

Through these strategies, the RER-T system promotes T cell-mediated anti-cancer activity on multiple levels, ultimately achieving significant anti-tumor effects in both in situ and postoperative B16-F10 tumor models.